Phaseline

Companies › Step Pharma, SAS

Step Pharma, SAS: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
STP938 (Dencatistat)–Phase 2Essential Thrombocythaemia; Solid Tumor; Lymphoma, B-CellDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06297525STP938 (Dencatistat)Phase 1Solid TumorOncologyDec 2026
NCT05463263STP938 (Dencatistat)Phase 1Lymphoma, B-CellOncologyDec 2026
NCT06786234STP938 (Dencatistat)Phase 2Essential ThrombocythaemiaOncologyJun 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.